‘Vitamin B17’: Killing more than cancer

Objective Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures. Methods A retrospective review of all amygdalin/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022. Results There were 120 unique exposure calls. Eighty‐two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican. Conclusion There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure. There was a total of 120 unique calls to New South Wales Poisons Information Centre regarding B17 use. There is evidence of ongoing supply, use and harm from illicit amygdalin/B17 products which carry risk of serious toxicity and increased health expenditure.